Analyzing MOX-allergic patients, the only group containing patients suffering from all 3 clinical entities, we have observed differences in the upregulated marker: in patients who suffered anaphylactic shock, an upregulation of CD203c was found, whereas patients with anaphylaxis showed a CD63 upregulation. This evidence concerns the gene CD63 and anaphylaxis.